A recent study indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional lifestyle regimens.
Findings released in a major medical journal shows that while obese people often shed a large proportion of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users buying such medications should be aware of the potential of fast rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to original mass within about one and a half years.
Analyzing Therapies
The study, which examined dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with other pills.
Scientists point out that people who shed pounds through lifestyle changes alone generally have a slower creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Experts suggest the way of the drugs accounts for the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means hunger is uncontrolled, making overeating far more likely."
An Ongoing Issue?
Medical guidelines recommend the jabs for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the likelihood of weight regain, the treatment might need to be long-term.
This opinion is supported by drug manufacturers, who note that the findings "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
People who have stopped the medication report a powerful return of hunger.
"It was like a trigger activating and you're instantly extremely hungry," recalled a patient.
The struggle is exacerbated if users have not developed permanent lifestyle or habit changes during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, experts caution that while these medications are effective agents for weight loss, they are not a magic fix and maintained weight loss relies on integrated lifestyle support.
